Introduction {#Sec1}
============

The antiplatelet drug clopidogrel---a second-generation thienopyridine with an absolute S configuration at carbon 7---is widely used in the prevention of ischemic events. In the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events) trial, clopidogrel was shown to be more effective than aspirin in reducing the risks of myocardial infarction, ischemic stroke and vascular death \[[@CR1]\]. Despite the obvious advantages of clopidogrel, many clinical studies have shown that approximately 5--40 % of patients treated with conventional doses of clopidogrel display inadequate antiplatelet responses, which may lead to serious cardiovascular complications \[[@CR2]\]. The mechanisms underlying this phenomenon have not yet been confirmed. It has been suggested that reduced efficacy of clopidogrel may be caused by genetic polymorphisms of the transporters and enzymes participating in clopidogrel absorption and metabolic transformation, and by non-genetic factors \[[@CR3]\]. The bioavailability of clopidogrel may be diminished because of secretion of the active drug by an efflux pump P-glycoprotein encoded by the multidrug resistance gene. This result may be reflected by visible inter-patient variability in the plasma concentrations of clopidogrel and its metabolites \[[@CR4]\].

Clopidogrel is a pro-drug and requires complex metabolic activation in the liver. Up to 85 % of the absorbed drug can be transformed by carboxyl esterases into a carboxylic acid derivative of clopidogrel (CLPM), the major metabolite circulating in the blood \[[@CR5]\]. Although this metabolite is inactive, its determination in plasma was used to study the pharmacokinetics of clopidogrel in an indirect manner for many years, because plasma concentrations of the parent drug are very low \[[@CR6]\]. Only 15 % of the absorbed clopidogrel dose is transformed by isoenzymes of cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C9, CYP2C19 and CYP3A4 to a thiol metabolite (CTM), which is responsible for the antithrombotic effect of clopidogrel \[[@CR7]\]. CTM selectively and irreversibly inhibits adenosine diphosphate (ADP)-induced platelet aggregation by directly blocking ADP binding to the P2Y12 receptor located on the platelet surface \[[@CR8]\]. Among the various CYP enzymes that catalyse the oxidative activation of clopidogrel, the CYP2C19 polymorphic variants \*2 and \*3 are mostly responsible for reduced exposure to CTM, leading to the decreased antiplatelet effect of clopidogrel in some patients \[[@CR9]\]. CTM is a chiral compound and may exist as four isomers (H1--H4), of which only H3 and H4 were present in the obtained clinical samples \[[@CR10]\]. In vitro studies have confirmed that the H4 isomer can be considered as the only active circulating isomer of CTM \[[@CR9], [@CR11]\]. Because of the analytical problems associated with low concentrations of the parent drug and the instability of its thiol derivative, only a small number of papers have focused on the pharmacokinetic aspects of clopidogrel treatment. The majority of these studies were performed in healthy volunteers and refer to the pharmacokinetics of the parent drug only \[[@CR12]\] or one of the metabolites, either CTM \[[@CR9], [@CR13]--[@CR16]\] or the inactive CLPM \[[@CR17]\]. In the cited papers on CTM pharmacokinetics, the specific parameters characterizing the metabolite were calculated for the mixture of CTM isomers. Because only the H4 isomer is clinically relevant, such an approach may lead to overestimation of patient exposure to the active metabolite of clopidogrel. Only Tuffal et al. \[[@CR10]\] distinguished between the pharmacokinetic parameters of the CTM isomers on the basis of their concentration in the plasma of healthy volunteers. That study was applicable only to CTM and did not consider the concentrations of clopidogrel or its main metabolite, CLPM. There is only one paper focusing on the pharmacokinetics of the parent drug and its two metabolites, CLPM and unstabilized CTM, in healthy volunteers. Because of the lack of a CTM standard, the concentration was approximated on the basis of the calibration curve prepared for clopidogrel \[[@CR18]\].

Because the patient response to clopidogrel treatment may be affected by the presence of specific co-morbidities (e.g. diabetes mellitus, chronic renal disease or obesity) and by co-administered medications (e.g. proton pump inhibitors \[PPIs\]) \[[@CR3]\], pharmacokinetic studies of clopidogrel and its metabolites would be especially useful in patients undergoing antiplatelet therapy. There are only a few reports on clopidogrel pharmacokinetics in patients treated with the drug. Erlinge et al. \[[@CR19]\] reported the pharmacokinetics of CTM as a mixture of isomers in patients with diabetes. The pharmacokinetics of clopidogrel, CLPM and CTM were investigated in patients with myocardial infarction, but the concentrations of CTM were very low because it was likely not stabilized in plasma samples \[[@CR20]\]. Moreover, Deray et al. \[[@CR21]\] described the pharmacokinetics of clopidogrel and CLPM but not those of the CTM isomers in patients with renal function impairment.

The objectives of this study were to investigate the pharmacokinetics of clopidogrel and its metabolites---the pharmacologically active H4, and the inactive H3 and CLPM---in patients treated with high and low doses of clopidogrel, to measure the pharmacodynamic effect of clopidogrel and to estimate the pharmacodynamic--pharmacokinetic correlation.

Patients and Methods {#Sec2}
====================

Study Population {#Sec3}
----------------

The study involved patients of Caucasian origin from central Poland undergoing elective coronary angiography, percutaneous coronary intervention, carotid artery stenting or peripheral artery interventions. Patients received an oral clopidogrel formulation under fasting conditions, either as a single 300 mg loading dose (*n* = 17) or as a 75 mg maintenance dose (*n* = 45) for 7 days prior to the procedure. Patients with acute myocardial infarction, malignancies, oral anticoagulation therapy with a coumarin derivative, treatment with a glycoprotein IIb/IIIa antagonist or other antiplatelet drugs except for aspirin, platelet count \<100,000/μL, current liver dysfunction or impaired renal function (serum creatinine concentration \>2 mg/dL) were excluded from the study. The study protocol was approved by the Ethical Committee at Poznan University of Medical Sciences, and all patients gave written informed consent for participation.

Sample Collection {#Sec4}
-----------------

Blood samples for quantification of plasma analyte concentrations were collected before administration of clopidogrel and at 0.5, 1, 2, 3, 4, 6, 12 and 24 h after administration. A 7.5 mL aliquot of blood was drawn into collection systems containing ethylenediaminetetraacetic potassium salt (EDTA-K) \[Sarstedt AG & Co., Nümbrecht, Germany\]. To stabilize the highly labile CTM, 37.5 μL of a 500 mM acetonitrile solution of 2-bromo-3′-methoxyacetophenone (MPB) was added to the systems, in accordance with the procedure reported by Takahashi et al. \[[@CR16]\]. The plasma was separated by centrifugation for 10 min at 1,620 × *g* and stored at −25 °C until further analysis.

Chemicals {#Sec5}
---------

(+)-S clopidogrel bisulfate (purity 99 %) and its carboxylic acid metabolite (CLPM; purity 99.6 %) were obtained from the Pharmaceutical Research Institute (Warsaw, Poland). The 3′-methoxyacetophenone derivatives of the clopidogrel thiol metabolite H3 (MP-H3) and H4 (MP-H4) isomers were a generous gift from Sanofi Aventis (Montpellier, France). Piroxicam, used as an internal standard, was obtained from Jelfa (Jelenia Góra, Poland). The alkylating agent MPB and formic acid (purity \>95 %) were purchased from Sigma-Aldrich Chemie (Steinheim, Germany). Acetonitrile (Merck, Darmstadt, Germany) was of the high-performance liquid chromatography (HPLC) gradient grade. De-ionized water was used to prepare a mobile phase for HPLC (Simplicity UV, Millipore, USA). Drug-free human plasma was obtained from the Regional Centre of Blood Donation (Poznań, Poland).

Determination of Clopidogrel and its Metabolite Concentrations in Plasma {#Sec6}
------------------------------------------------------------------------

In the samples stabilized with MPB (from 3 patients treated with clopidogrel 300 mg and from 41 patients treated with 75 mg), the concentrations of clopidogrel, CLPM and the H3 and H4 isomers of CTM were measured by a validated HPLC method with tandem mass spectrometry (MS/MS) \[[@CR22]\]. Briefly, 250 μL of plasma was spiked with 25 μL of internal standard solution at a concentration of 100 ng/mL. Protein precipitation was performed by adding 450 μL of acetonitrile to each sample. The mixture was vortexed and centrifuged for 10 min at 22,570 × *g* and a temperature of 20 °C before the supernatant was filtered using Mini Uni Prep filters (Whatman International Ltd., Maidstone, Kent, UK). The resulting filtrate was evaporated under a vacuum at 40 °C, and the dry residue was reconstituted in 200 μL of the mobile phase. A 25 μL aliquot was injected onto the HPLC--MS/MS system. The HPLC analysis was performed on a chromatograph Agilent 1200, which was coupled to a 6410 B Triple Quadrupole tandem mass spectrometer (both from Agilent Technologies, Palo Alto, CA, USA). The analytes were separated in the Zorbax Plus C18 column \[100 mm × 2.1 mm, 3.5 μm\] (Agilent Technologies, USA) at a column temperature of 40 °C. The mobile phase was a mixture of de-ionized water (A) and acetonitrile (B), both containing 0.1 % (v/v) formic acid. The gradient was as follows: 0--7 min linear from 42 to 90 % B, 7--7.5 min return from 90 to 42 % B and post-time of 5 min with 42 % B for column equilibration. The mobile phase flow was set at 0.35 mL/min. The eluent from the HPLC column was introduced directly to the MS interface, using electrospray ionization in the positive ion mode. The MS parameters were as follows: capillary voltage 4,000 V, nebulizer gas (nitrogen) pressure 40 psi (275.8 kPa), desolvation gas (nitrogen) flow 10 L/min and desolvation temperature 300 °C. Nitrogen was used as a collision gas. The specific transitions for the analytes were monitored using the multiple reaction monitoring (MRM) mode. The most sensitive mass transition was from m/z 322.1 to 212 for clopidogrel, from m/z 504.1 to 155 for the CTM isomers, from m/z 308.1 to 198 for CLPM and from m/z 332.1 to 95 for the internal standard. The method was linear in the ranges of 0.25--5.00 ng/mL for clopidogrel, 0.25--50.00 ng/mL for the MP-H3 and MP-H4 isomers, and 50--10,000 ng/mL for CLPM. The lower limits of quantitation (LLOQs) were 0.25 ng/mL for clopidogrel, MP-H3 and MP-H4, and 50.00 ng/mL for CLPM. The intra- and inter-assay precision values, expressed as relative standard deviations, were ≤18.1 % for clopidogrel, ≤15.2 % for CLPM, ≤10.1 % for MP-H3 and ≤19.9 % for MP-H4. The intra- and inter-day accuracy of the method, expressed as the relative error, was ≤16 %. The analytes were stable in samples stored for 6 h in the autosampler, and in plasma samples stored for 24 h at room temperature and for 3 months at −25 °C \[[@CR22]\].

In plasma samples not treated with MPB (from 14 patients treated with clopidogrel 300 mg and from 4 patients treated with 75 mg), only the concentrations of CLPM were measured by a validated high-performance capillary electrophoresis method with diode array detection, as described by Karaźniewicz-Łada et al. \[[@CR23]\]. Briefly, 1 mL of plasma was mixed with 50 μL of the internal standard at a concentration of 10 mg/L and 1 mL of phosphoric buffer at pH 5.0. The analytes were extracted by a solid-phase extraction procedure on C18 columns (Bakerbond SPE™; J.T. Baker, Deventer, The Netherlands) and determined on an Agilent model ^3D^CE apparatus (Agilent Technologies, Waldbronn, Germany) with the ultraviolet detector set at λ = 220 nm. The samples were automatically injected using a hydrodynamic injection at the anode. The temperature of the capillary was maintained by a thermostatic system at 25 °C. The separation was performed in a fused silica capillary, 35 cm × 50 μm i.d., 26.5 cm to the detector, filled with a 0.025 M phosphate buffer of pH 2.5. The system was controlled by ChemStation software. All experiments were performed at 25 kV and a 50 × 5 mbar·s injection (12 nL injected volume). The method was linear in the range of 0.5--10 mg/L for clopidogrel and 0.25--20 mg/L for CLPM. The intra- and inter-day accuracy and precision of the method were below 12 %. The recovery of the analytes from plasma samples was ≥80 % \[[@CR23]\].

Pharmacodynamic Assay {#Sec7}
---------------------

Whole-blood platelet aggregation was measured in 38 patients receiving clopidogrel 75 mg daily. The samples for the aggregation assay were collected, 2--3 h after clopidogrel administration, in an S-Monovette system coated with hirudin (Sarstedt AG & Co.). The measurements were performed using an impedance aggregometer (Multiplate^®^ analyser; Roche Diagnostics, Mannheim, Germany). After a 1:1 dilution of whole blood with 0.9 % NaCl solution and stirring for 3 min in the test cuvettes at 37 °C, 6.4 μmol/L of ADP was added, and the increase in electrical impedance was recorded continuously for 6 min. The platelet aggregation was quantified as arbitrary units (AU) and the area under the curve of the arbitrary units (AU·min). According to the recent consensus opinion of Bonello et al. \[[@CR24]\], a cut-off point of 468 AU·min for platelet aggregation in response to ADP should be used as the threshold for an increased risk of thrombotic events during clopidogrel therapy. All materials used for platelet function testing were obtained from the manufacturer.

Pharmacokinetic Calculations {#Sec8}
----------------------------

The plasma concentrations of clopidogrel, CLPM, H3 and H4 were used to calculate the pharmacokinetic parameters, using WinNonlin version 6.2 software (Pharsight, Mountain View, CA, USA). For the calculation, the non-compartmental technique was applied. The total area under the concentration--time curve (AUC) was estimated by the trapezoidal rule with extrapolation from time zero to infinity (AUC~∞~), using *C*~last~/*k*~el~, where *C*~last~ is the last measurable concentration and *k*~el~ is the elimination rate constant calculated from the terminal linear segment of the log plasma concentration--time data. The elimination half-life (*t*~½~) was estimated from ln2/*k*~el~. The maximum plasma concentration (*C*~max~) and the time to reach the *C*~max~ (*t*~max~) were derived directly from the observed plasma concentrations. The plasma drug clearance (CL/*F*) was calculated by dividing the dose (*D*) of each enantiomer by the AUC~∞~, assuming complete biological accessibility. The volume of distribution (*V*~d~/*F*) was estimated from *D*/*k*~el~ × AUC~∞~.

Statistical Analysis {#Sec9}
--------------------

The statistical analysis was performed using Statistica version 8.0 software (StatSoft Inc., Tulsa, OK, USA). The coefficient of variation (CV %) was calculated as (mean/SD × 100). Normality was estimated with the Shapiro--Wilk test. The differences between the normally distributed variables were determined with the Student's *t* test; in the other cases, the Mann--Whitney test was applied. Correlations between the parameters were calculated with the Spearman rank correlation coefficient for all non-normally distributed values. A *p* value of \<0.05 was considered significant.

Results {#Sec10}
=======

Patient Characteristics {#Sec11}
-----------------------

The detailed characteristics of the subjects are presented in Table [1](#Tab1){ref-type="table"}. No statistically relevant differences were observed in the age, bodyweight and body mass index between the patient groups.Table 1Patient characteristicsCharacteristicClopidogrel 75 mg (*n* = 45)Clopidogrel 300 mg (*n* = 17)Age \[years; mean ± SD\]63.0 ± 8.564.9 ± 9.9Bodyweight \[kg; mean ± SD\]81.8 ± 13.380.4 ± 6.6Body mass index \[kg/m^2^; mean ± SD\]27.8 ± 5.427.8 ± 3.2Female sex \[*n*\]140Carotid artery stenting \[*n*\]310Coronary angiography \[*n*\]160Percutaneous coronary intervention \[*n*\]250Peripheral artery intervention \[*n*\]17Hypertension \[*n*\]378Hypercholesterolaemia \[*n*\]72Diabetes mellitus \[*n*\]156Dyslipidaemia \[*n*\]88Proton-pump inhibitors \[*n*\]184Statins \[*n*\]4214Beta-blockers \[*n*\]377ACE inhibitors \[*n*\]309*ACE* angiotensin-converting enzyme, *SD* standard deviation

Determination of Clopidogrel and Its Metabolite Concentrations in Plasma {#Sec12}
------------------------------------------------------------------------

The mean plasma concentration--time profiles of clopidogrel, CLPM and the H3 and H4 isomers of CTM obtained in patients following administration of clopidogrel at doses of 75 and 300 mg are presented in Fig. [1](#Fig1){ref-type="fig"}. As suggested by Tuffal et al. \[[@CR10]\], the samples with poor signs of haemolysis after addition of MPB (48 out of a total of 358 samples) were considered as not sufficiently stabilized, and their concentrations of H3 and H4 were not taken into account during the pharmacokinetic calculations.Fig. 1Mean plasma concentrations of (**a**) clopidogrel (CLP), (**b**) the carboxylic acid metabolite of clopidogrel (CLPM), (**c**) the H3 isomer of the clopidogrel thiol metabolite (CTM) and (**d**) the H4 isomer of CTM versus time following administration of clopidogrel 75 mg and 300 mg to patients

Pharmacokinetic Parameters {#Sec13}
--------------------------

The pharmacokinetic parameters calculated for clopidogrel, CLPM and the H3 and H4 isomers of CTM after administration of clopidogrel 75 and 300 mg are presented in Table [2](#Tab2){ref-type="table"}. Clopidogrel was absorbed rapidly from the gastrointestinal tract, with *C*~max~ values of 2 and 4.5 ng/mL following administration of clopidogrel 75 and 300 mg, respectively, and *t*~max~ values of 1.4 and 1.2 h, respectively. The low plasma concentrations of clopidogrel resulted from its rapid metabolism. The main clopidogrel metabolite, which is the biologically inactive CLPM, reached a *C*~max~ in plasma that was a thousand-fold greater than that of the parent drug (Fig. [1](#Fig1){ref-type="fig"}b). The second metabolite, which is a thiol derivative of clopidogrel, was quantifiable in plasma as the H3 and H4 isomers exhibiting similar pharmacokinetic profiles (Fig. [1](#Fig1){ref-type="fig"}c, d). The plasma concentrations of the biologically active H4 isomer following administration of clopidogrel 75 mg were slightly higher than those of its antipode, the inactive H3, whereas after a dose of 300 mg, the exposure to H4 was two times greater than the exposure to the H3 isomer (Table [2](#Tab2){ref-type="table"}). The results were, however, strongly biased by the small number of subjects in the clopidogrel 300 mg group. The H3 and H4 isomers were eliminated rapidly, and their concentrations were below the limit of quantification at 6 h after clopidogrel administration in most subjects. CLPM was characterized by the slowest elimination rate, with a *t*~½~ of approximately 7 h.Table 2Pharmacokinetic parameters of clopidogrel, the carboxylic acid metabolite of clopidogrel (CLPM) and the H3 and H4 isomers of the clopidogrel thiol metaboliteParameterClopidogrelH3H4 (active)CLPMDose: clopidogrel 75 mg(*n* = 41)(*n* = 30)(*n* = 30)(*n* = 45) *C* ~max~ \[ng/mL; mean ± SD\]2.04 ± 2.05.29 ± 5.547.13 ± 6.322,516 ± 1,754 *t* ~max~ \[h; mean ± SD\]1.40 ± 1.071.08 ± 0.621.04 ± 0.531.37 ± 0.74 *t* ~½~ \[h; mean ± SD\]1.71 ± 1.280.78 ± 0.780.90 ± 0.867.14 ± 3.32 AUC~*t*~ \[ng·h/mL; mean ± SD\]5.07 ± 3.807.37 ± 6.7111.30 ± 9.5811,077 ± 7,768 AUC~∞~ \[ng·h/mL; mean ± SD\]6.29 ± 4.117.96 ± 6.8511.97 ± 9.7512,383 ± 8,552 CL/*F* \[×10^3^ L/h; mean ± SD\]18.96 ± 15.89------ *V* ~d~/*F* \[×10^3^ L; mean ± SD\]39.24 ± 33.52------Dose: clopidogrel 300 mg(*n* = 3)(*n* = 3)(*n* = 3)(*n* = 17) *C* ~max~ \[ng/mL; mean ± SD\]4.51 ± 3.428.47 ± 1.6917.92 ± 20.388,464 ± 3,772 *t* ~max~ \[h; mean ± SD\]1.17 ± 0.760.83 ± 0.290.83 ± 0.291.61 ± 1.21 *t* ~½~ \[h; mean ± SD\]1.99 ± 0.440.72 ± 0.180.84 ± 0.207.11 ± 3.50 AUC~*t*~ \[ng·h/mL; mean ± SD\]20.82 ± 13.3511.24 ± 8.3125.04 ± 27.4132,979 ± 12,321 AUC~∞~ \[ng·h/mL; mean ± SD\]21.76 ± 13.3411.70 ± 8.3325.69 ± 27.5437,249 ± 13,861 CL/*F* \[×10^3^ L/h; mean ± SD\]16.98 ± 10.41------ *V* ~d~/*F* \[×10^3^ L; mean ± SD\]45.50 ± 19.22------*AUC* area under the plasma concentration--time curve, *AUC* ~*t*~ AUC from time zero to time *t*, *AUC* ~*∞*~ AUC from time zero to infinity, *CL/F* plasma drug clearance, *C* ~*max*~ maximum plasma concentration, *t* ~*½*~ elimination half-life, *t* ~*max*~ time to reach the *C* ~max~, *V* ~*d*~ */F* volume of distribution

The statistical analysis showed that the plasma concentrations of clopidogrel and its metabolites at 1--6 h for clopidogrel, 1--3 h for H3, 0.5--2 h for H4 and 1--24 h for CLPM were significantly correlated with their *C*~max~, AUC~*t*~ and AUC~∞~ values. A significant correlation was found between the AUC~*t*~ of the active H4 isomer and the *C*~max~ (*r* = 0.466, *p* = 0.019) and AUC~*t*~ (*r* = 0.434, *p* = 0.049) of the parent drug. The differences between the pharmacokinetic parameters of the H3 and H4 isomers calculated after administration of clopidogrel 75 mg were not statistically significant. We did not observe any statistically significant influence of age, diabetes mellitus or co-administration of CYP2C19 inhibitors (mainly PPIs---omeprazole and pantoprazole) on exposure to the H3 and H4 isomers (Table [3](#Tab3){ref-type="table"}).Table 3Influence of baseline characteristics on systemic exposure to the H3 and H4 isomers of the clopidogrel thiol metabolite in patients receiving clopidogrel 75 mgCharacteristicH3 *C* ~max~\
\[ng/mL; mean ± SD\]H3 AUC~*t*~\
\[ng·h/mL; mean ± SD\]H4 *C* ~max~\
\[ng/mL; mean ± SD\]H4 AUC~*t*~\
\[ng·h/mL; mean ± SD\]Age ≥65 years (*n* = 13)6.22 ± 6.838.13 ± 8.447.91 ± 5.9110.40 ± 8.07 \<65 years (*n* = 17)4.57 ± 4.416.34 ± 4.806.54 ± 6.7411.48 ± 11.03 *p* value0.2670.6290.2330.923Diabetes mellitus Yes (*n* = 11)5.96 ± 7.697.88 ± 9.338.04 ± 6.5511.69 ± 9.63 No (*n* = 19)4.90 ± 4.026.71 ± 4.476.61 ± 6.3010.46 ± 9.78 *p* value0.6510.6550.4780.805Proton-pump inhibitors Yes (*n* = 13)5.94 ± 6.637.76 ± 8.169.04 ± 8.0713.10 ± 9.82 No (*n* = 15)5.00 ± 4.937.03 ± 5.525.92 ± 4.539.69 ± 9.81 *p* value0.4750.9800.3940.277*AUC* ~*t*~ area under the plasma concentration--time curve from time zero to time *t*, *C* ~*max*~ maximum plasma concentration

Pharmacodynamic Assay {#Sec14}
---------------------

Platelet aggregation measured in patients treated with a maintenance dose of clopidogrel 75 mg ranged between 37 and 747 AU·min (mean ± SD 166 ± 146 AU·min, median 141 AU·min). Only two patients could be characterized as non-responders, with AUC values \>468 AU·min, and 14 patients had low platelet aggregation, with AUC values \<100 AU·min. Initially, the statistical analysis showed no correlation between platelet aggregation and the pharmacokinetic parameters, such as the *C*~max~ and AUC~*t*~ of clopidogrel and its metabolites, but one patient with a high value of platelet aggregation (AUC 637 AU·min) exhibited high concentrations of the active H4 isomer (*C*~max~ 23.3 ng/mL). After excluding that patient from the study, the statistical analysis revealed that ADP-induced platelet aggregation was strongly associated with the *C*~max~ of the active H4 isomer \[*r* = −0.439, *p* = 0.025\] (Fig. [2](#Fig2){ref-type="fig"}d). There was a trend towards a correlation of platelet aggregation and the *C*~max~ of the H3 isomer \[*r* = −0.374, *p* = 0.063\] (Fig. [2](#Fig2){ref-type="fig"}c).Fig. 2Correlation between platelet aggregation and the maximum plasma concentration (*C* ~max~) of (**a**) clopidogrel (CLP), (**b**) the carboxylic acid metabolite of clopidogrel (CLPM), (**c**) the H3 isomer of the clopidogrel thiol metabolite (CTM) and (**d**) the H4 isomer of CTM in patients receiving clopidogrel 75 mg. The *solid lines* represent the linear regression fit to the data. *AU* arbitrary units

Discussion {#Sec15}
==========

To investigate the pharmacokinetics of clopidogrel and its main metabolites (CLPM and the H3 and H4 isomers of CTM) in the studied population, an HPLC--MS/MS method was developed for simultaneous determination of all of these analytes in patient plasma samples \[[@CR22]\]. The method was adequately accurate and precise and fulfilled the validation requirements for quantitative analysis of drugs and their metabolites in biological samples. The method offered an improved LLOQ (0.25 ng/mL) of the CTM isomers compared with the LLOQ of 0.5 ng/mL previously described by Tuffal et al. \[[@CR10]\]. The majority of the developed HPLC--MS/MS assays for determination of the active thiol metabolite of clopidogrel do not distinguish between the H3 and H4 isomers of the compound \[[@CR16], [@CR25], [@CR26]\] and may lead to overestimation of patient exposure to the active metabolite. In the present study, application of the selective HPLC--MS/MS method permitted investigation into the pharmacokinetics of the clinically relevant H4 isomer and the parent drug and its non-active metabolites, H3 and CLPM.

Pharmacokinetic data on clopidogrel, CLPM, and the H3 and H4 isomers of CTM are scarce and have mainly been determined in healthy volunteers. Several reports in the literature have indicated that the ethnic background of subjects has an influence on the pharmacokinetics of the parent drug. According to the published data, the *C*~max~ values of clopidogrel varied from 0.9 ng/mL in Argentinean subjects \[[@CR27]\] to 4.4 ng/mL in Egyptian healthy volunteers \[[@CR28]\] following administration of clopidogrel 75 mg. The *C*~max~ of 2.0 ng/mL obtained in the present study following the same dose is similar to the *C*~max~ values of 1.5 and 2.5 ng/mL reported by Hurbin et al. \[[@CR29]\] in US healthy volunteers in the fasted and fed states, respectively. A possible reason for the ethnicity-specific responses is significant variability in the frequencies of the *CYP2C19* allelic variants found in different ethnic groups, which may affect the metabolism of clopidogrel \[[@CR30]\]. Clopidogrel pharmacokinetics in patients with cardiovascular disease may differ from those in healthy subjects. Sibbing et al. \[[@CR31]\] reported diminished conversion of clopidogrel into its active thiol metabolite in patients with a history of stent thrombosis following percutaneous coronary intervention. This was reflected by a significantly lower *C*~max~ of CTM in patients (3.2 ng/mL) than in healthy control subjects (14.5 ng/mL) following administration of clopidogrel 600 mg. A similar conclusion may be drawn from the results of the present study, where the *C*~max~ values of the H3 and H4 isomers of CTM were 5.29 and 7.13 ng/mL, respectively (Table [2](#Tab2){ref-type="table"}), and were lower than those reported in healthy volunteers, according to the literature data. Following the same dose of clopidogrel 75 mg, Tuffal et al. \[[@CR10]\] observed *C*~max~ values of 17.8 ng/mL for H3 and 16.4 ng/mL for the H4 isomer, but in the study by Furlong et al. \[[@CR32]\], a *C*~max~ of 11 ng/mL for the H4 isomer was reported. We could speculate that conversion of clopidogrel into the H4 active isomer of the thiol metabolite was diminished in the studied group of patients, compared with healthy volunteers. One possible reason for this is impaired blood flow to the body tissues associated with cardiovascular disorders. This may result in decreased drug absorption and impaired metabolism of the drug in the liver. The higher CTM concentrations (\>20 ng/mL) in plasma obtained by Peer et al. \[[@CR26]\] resulted from application of a validated HPLC--MS/MS method that did not distinguish between the H3 and H4 isomers. Geisler et al. \[[@CR33]\] reported that an impaired response to clopidogrel treatment may be predicted by certain factors, such as advanced age (\>65 years), a history of acute coronary syndromes, diabetes mellitus or renal failure. These variables may also have an influence on systemic exposure to the CTM isomers. In our study, neither age nor diabetes mellitus was significantly associated with the *C*~max~ or AUC~*t*~ of the H3 and H4 isomers (Table [3](#Tab3){ref-type="table"}). The multivariate analysis of variance showed no association between the combination of these variables and the pharmacokinetic parameters of the CTM isomers.

As demonstrated by the aforementioned studies, the pharmacokinetics of clopidogrel and CTM are highly variable, with a CV of 50--80 % for the calculated pharmacokinetic parameters \[[@CR10], [@CR29], [@CR32]\]. The inter-subject variability was even more pronounced in the studied group of patients (CV \>100 %) and requires further explanation with reference to genetic polymorphisms of the ABCB1 and CYP isoenzymes, co-morbidities and drug--drug interactions. Identification of the sources that influence both the pharmacokinetic and pharmacodynamic responses may be difficult because it is unclear whether these factors fully explain the variability of the response to clopidogrel treatment. In a study by Frelinger et al. \[[@CR34]\]---despite rigorous elimination of variations in CYP2C19 polymorphisms, compliance, diet, nicotine and prescribed medications, including PPIs and statins---clopidogrel pharmacokinetics and pharmacodynamics varied widely in the studied group of healthy volunteers. The authors estimated that unidentified factors accounted for 82 and 64 % of inter-subject variation in the pharmacokinetic parameters and pharmacodynamics responses, respectively.

In the present study, variability in clopidogrel pharmacodynamics measured by ADP-induced platelet aggregation was observed, and it was associated with plasma concentrations of the CTM isomers. The significant correlation between the *C*~max~ of the active H4 isomer and platelet aggregation indicates the usefulness of both factors as predictors of the patient response to clopidogrel therapy. The high platelet aggregation (747 AU·min) coexisting with low plasma concentrations of the H4 isomer (*C*~max~ 2.5 ng/mL) determined in one subject suggests a poor response to clopidogrel treatment and may lead to development of serious cardiovascular complications. According to the recent consensus opinion of Bonello et al. \[[@CR24]\], platelet aggregation \>468 AU·min in response to ADP as measured with the Multiplate analyser is a criterion for identification of patients at high risk of thrombotic events.

Some studies have demonstrated that monitoring of platelet function may be especially useful in patients with decreased clopidogrel metabolism. Such patients may be identified by genetic studies as carriers of the loss-of-function *CYP2C19\*2* alleles \[[@CR35], [@CR36]\].

Pharmacokinetic analysis of clopidogrel and its metabolites, especially the active H4 isomer, may be a useful tool for identification of patients who are at risk of high on-treatment platelet reactivity. Routine monitoring of platelet aggregation and H4 plasma concentrations during clopidogrel treatment may improve clinical outcomes in patients with cardiovascular diseases.

A significant correlation between concentrations at individual timepoints and the pharmacokinetic parameters *C*~max~, AUC~*t*~ and AUC~∞~ of clopidogrel and its metabolites (see Sect. [3.3](#Sec13){ref-type="sec"}) suggests that less frequent monitoring of plasma concentrations for prediction of total drug exposure may be possible. The results might be useful for designing a limited-sampling strategy in which accurate information on the antiplatelet effect of clopidogrel can be obtained using plasma concentrations determined in a few blood samples at appropriate times. Strategies using a limited number of samples have proven to be useful in therapeutic monitoring of immunosuppressants \[[@CR37]\] or anti-infective agents \[[@CR38]\]. A significant correlation between the pharmacokinetic parameters of clopidogrel and the AUC~*t*~ of the H4 isomer allows for prediction of patient exposure to the active metabolite in situations when only analysis of the parent compound is available.

Conclusion {#Sec16}
==========

To our knowledge, this is the first study of the pharmacokinetics of clopidogrel and its main metabolites, the active H4 and inactive H3 and CLPM, in patients with cardiovascular diseases. Our results confirmed that pharmacokinetic data in healthy volunteers are not sufficient for accurate prediction of the therapeutic effect of clopidogrel in clinical conditions. The *C*~max~ of the active H4 isomer and platelet aggregation measured with the Multiplate analyser may serve as indicators of the patient response to clopidogrel therapy. The differences in the pharmacokinetic parameters of clopidogrel and its metabolites that were found in the studied group suggest that further studies of genetic and non-genetic sources of inter-individual variability should be performed.
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